162 related articles for article (PubMed ID: 16408696)
21. Laromustine, a sulfonyl hydrolyzing alkylating prodrug for cancer therapy.
Pigneux A
IDrugs; 2009 Jan; 12(1):39-53. PubMed ID: 19127504
[TBL] [Abstract][Full Text] [Related]
22. Enhancement of platinum-induced cytotoxicity by O6-benzylguanine.
Fishel ML; Delaney SM; Friesen LD; Hansen RJ; Zuhowski EG; Moschel RC; Egorin MJ; Dolan ME
Mol Cancer Ther; 2003 Jul; 2(7):633-40. PubMed ID: 12883036
[TBL] [Abstract][Full Text] [Related]
23. Point mutations in human O6-alkylguanine-DNA alkyltransferase prevent the sensitization by O6-benzylguanine to killing by N,N'-bis (2-chloroethyl)-N-nitrosourea.
Loktionova NA; Pegg AE
Cancer Res; 1996 Apr; 56(7):1578-83. PubMed ID: 8603405
[TBL] [Abstract][Full Text] [Related]
24. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
Spiro T; Liu L; Gerson S
Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
[TBL] [Abstract][Full Text] [Related]
25. Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy.
Rabik CA; Njoku MC; Dolan ME
Cancer Treat Rev; 2006 Jun; 32(4):261-76. PubMed ID: 16698182
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme.
Badruddoja MA; Penne K; Desjardins A; Reardon DA; Rich JN; Quinn JA; Sathornsumetee S; Friedman AH; Bigner DD; Herndon JE; Cahill A; Friedman HS; Vredenburgh JJ
Neuro Oncol; 2007 Jan; 9(1):70-4. PubMed ID: 17108065
[TBL] [Abstract][Full Text] [Related]
27. O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair.
Spiro TP; Gerson SL; Liu L; Majka S; Haaga J; Hoppel CL; Ingalls ST; Pluda JM; Willson JK
Cancer Res; 1999 May; 59(10):2402-10. PubMed ID: 10344750
[TBL] [Abstract][Full Text] [Related]
28. Effect of O6-benzylguanine on nitrogen mustard-induced toxicity, apoptosis, and mutagenicity in Chinese hamster ovary cells.
Cai Y; Ludeman SM; Wilson LR; Chung AB; Dolan ME
Mol Cancer Ther; 2001 Nov; 1(1):21-8. PubMed ID: 12467235
[TBL] [Abstract][Full Text] [Related]
29. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
Rhines LD; Sampath P; Dolan ME; Tyler BM; Brem H; Weingart J
Cancer Res; 2000 Nov; 60(22):6307-10. PubMed ID: 11103789
[TBL] [Abstract][Full Text] [Related]
30. Isolation of human O6-alkylguanine-DNA alkyltransferase mutants highly resistant to inactivation by O6-benzylguanine.
Xu-Welliver M; Kanugula S; Pegg AE
Cancer Res; 1998 May; 58(9):1936-45. PubMed ID: 9581836
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and antitumor activity evaluation of a novel combi-nitrosourea prodrug: Designed to release a DNA cross-linking agent and an inhibitor of O(6)-alkylguanine-DNA alkyltransferase.
Sun G; Zhang N; Zhao L; Fan T; Zhang S; Zhong R
Bioorg Med Chem; 2016 May; 24(9):2097-107. PubMed ID: 27041398
[TBL] [Abstract][Full Text] [Related]
32. Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase.
Friedman HS; Pegg AE; Johnson SP; Loktionova NA; Dolan ME; Modrich P; Moschel RC; Struck R; Brent TP; Ludeman S; Bullock N; Kilborn C; Keir S; Dong Q; Bigner DD; Colvin OM
Cancer Chemother Pharmacol; 1999; 43(1):80-5. PubMed ID: 9923545
[TBL] [Abstract][Full Text] [Related]
33. Conserved residue lysine165 is essential for the ability of O6-alkylguanine-DNA alkyltransferase to react with O6-benzylguanine.
Xu-Welliver M; Kanugula S; Loktionova NA; Crone TM; Pegg AE
Biochem J; 2000 Apr; 347(Pt 2):527-34. PubMed ID: 10749683
[TBL] [Abstract][Full Text] [Related]
34. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.
Liu L; Markowitz S; Gerson SL
Cancer Res; 1996 Dec; 56(23):5375-9. PubMed ID: 8968088
[TBL] [Abstract][Full Text] [Related]
35. Influence of phosphate and phosphoesters on the decomposition pathway of 1,2-bis(methylsulfonyl)-1-(2-chloroethyhydrazine (90CE), the active anticancer moiety generated by Laromustine, KS119, and KS119W.
Penketh PG; Shyam K; Zhu R; Baumann RP; Ishiguro K; Sartorelli AC
Chem Res Toxicol; 2014 May; 27(5):818-33. PubMed ID: 24618018
[TBL] [Abstract][Full Text] [Related]
36. Effect of cloretazine (VNP40101M) on acute myeloid leukaemia blast cells in vitro as a single agent and combined with cytarabine and daunorubicin.
Morris KL; Adams JA; Liu Yin JA
Leuk Res; 2009 Aug; 33(8):1096-9. PubMed ID: 19268363
[TBL] [Abstract][Full Text] [Related]
37. Can O6-alkylguanine-DNA alkyltransferase depletion enhance alkylator activity in the clinic?
Friedman HS
Clin Cancer Res; 2000 Aug; 6(8):2967-8. PubMed ID: 10955771
[No Abstract] [Full Text] [Related]
38. Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents.
Dolan ME; Mitchell RB; Mummert C; Moschel RC; Pegg AE
Cancer Res; 1991 Jul; 51(13):3367-72. PubMed ID: 1647266
[TBL] [Abstract][Full Text] [Related]
39. Comparison of DNA lesions produced by tumor-inhibitory 1,2-bis(sulfonyl)hydrazines and chloroethylnitrosoureas.
Penketh PG; Shyam K; Sartorelli AC
Biochem Pharmacol; 2000 Feb; 59(3):283-91. PubMed ID: 10609557
[TBL] [Abstract][Full Text] [Related]
40. Differential sensitivity of human and mouse alkyltransferase to O6-benzylguanine using a transgenic model.
Liu L; Lee K; Wasan E; Gerson SL
Cancer Res; 1996 Apr; 56(8):1880-5. PubMed ID: 8620508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
